Lexicon Pharmaceuticals, Inc. LXRX
1.80
(0.06)
(3.23%)
as of 25 Sep
- Market cap
- $854.3M
- P/E
- 0.0×
Follow LXRX
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
25.33 | 8.97 | 8.38 | 6.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(114.27) | (42.39) | (24.23) | (20.58) | |
P/B ratio |
6.02 | 3.08 | 3.88 | 4.08 | |
Price to Tangible BV |
8.08 | 3.94 | 6.63 | 6.49 | |
EV/Sales |
22.08 | 7.29 | 7.54 | 6.68 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.09) | (13.09) | (5.53) | (6.56) | |
EV/FCF |
(13.87) | (12.75) | (5.45) | (6.47) | |
Quick Ratio |
13.07 | 18.43 | 4.73 | 5.45 | |
Current Ratio |
13.37 | 18.79 | 4.88 | 5.64 | |
Net Debt/EBITDA |
5.37 | 590.12 | 2.98 | 5.11 | |
Debt/Assets |
20.57% | 18.48% | 29.19% | 27.44% | |
Debt/Equity |
0.29 | 0.24 | 0.50 | 0.47 | |
Asset Turnover |
0.17 | 0.25 | 0.21 | 0.27 | |
Operating CF/Net income |
0.29 | 14.12 | 1.11 | 1.87 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,520.66% | 60.45% | 205.97% | 132.26% | |
Selling, General and Administrative Expense of Revenue |
1,408.96% | 43.76% | 159.46% | 53.60% | |
Intangible Assets out of Total Assets |
0.18 | 0.17 | 0.24 | 0.22 | |
Share Based Compensation of Revenue |
482.08% | 14.59% | 51.61% | 24.28% | |
Graham Net Nets |
0.12 | 0.19 | 0.06 | 0.07 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.36%) | (4.65%) | (12.17%) | (14.07%) | |
Free Cash Flow Yield |
(6.29%) | (6.38%) | (16.50%) | (14.91%) | |
Revenue per Share |
0.00 | 0.05 | 0.02 | 0.04 | |
Operating CF per Share |
(0.02) | (0.04) | (0.05) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.04) | (0.05) | (0.07) | |
Cash per Share |
0.44 | 0.43 | 0.27 | 0.32 | |
Shareholders Equity per Share |
0.40 | 0.51 | 0.30 | 0.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.40 | 0.51 | 0.30 | 0.33 | |
Free Cash Flow |
(9.19) | (14.73) | (17.23) | (23.83) | |
Working Capital |
181.87 | 176.13 | 81.03 | 100.81 | |
Net Current Asset Value |
121.04 | 120.07 | 24.45 | 36.76 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(4,591.76%) | (4.94%) | (282.71%) | (90.04%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.91 | 29.61 | 2.93 | 2.61 | |
Average Payables |
4.12 | 6.84 | 8.94 | 9.00 | |
Average Inventory |
0.68 | 0.24 | 0.26 | 0.40 | |
Average Assets |
237.82 | 283.25 | 241.70 | 263.53 | |
Average Common Equity |
151.98 | 162.94 | 126.74 | 149.34 |
Columns are period end dates